Heart Test Laboratories Inc
NASDAQ:HSCS
Heart Test Laboratories Inc
Heart Test Laboratories Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Southlake, Texas and currently employs 12 full-time employees. The company went IPO on 2022-06-15. Heart Test Laboratories, Inc. is a medical technology company focused on developing artificial intelligence (AI) based technology to an electrocardiogram (ECG) to expand and improve an ECG’s clinical usefulness. The Company’s product candidate, the MyoVista wavECG, or the MyoVista, is designed to provide diagnostic information related to cardiac dysfunction. The MyoVista is a 12-lead resting ECG device that features its algorithm developed to detect cardiac dysfunction in the diastolic phase, specifically slower than normal left ventricular relaxation rates. The MyoVista uses electrical information from the heart captured during a standard resting 12-lead ECG test as inputs to an artificial intelligence-based algorithm. The MyoVista detects whether a patient is negative or positive for abnormally slow left ventricular diastolic relaxation rates.
Heart Test Laboratories Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Southlake, Texas and currently employs 12 full-time employees. The company went IPO on 2022-06-15. Heart Test Laboratories, Inc. is a medical technology company focused on developing artificial intelligence (AI) based technology to an electrocardiogram (ECG) to expand and improve an ECG’s clinical usefulness. The Company’s product candidate, the MyoVista wavECG, or the MyoVista, is designed to provide diagnostic information related to cardiac dysfunction. The MyoVista is a 12-lead resting ECG device that features its algorithm developed to detect cardiac dysfunction in the diastolic phase, specifically slower than normal left ventricular relaxation rates. The MyoVista uses electrical information from the heart captured during a standard resting 12-lead ECG test as inputs to an artificial intelligence-based algorithm. The MyoVista detects whether a patient is negative or positive for abnormally slow left ventricular diastolic relaxation rates.
